HepHIV 5 - 7 May 2021 (Time CEST) / Lisbon & Virtual
EATG Stakeholders Meeting Regarding Diagnostics HepHIV 2021 conference side-meeting
Time: 5 May 2021, 9:30-11:00 CEST
Participants: Diagnostics companies, EuroTEST, ECDC, WHO, community and civil society organizations providing screening services.
Meeting background
The WHO and ECDC have recommended that early detection and treatment of HIV and viral hepatitis among key populations in Europe could be enhanced by implementing self-testing/sampling options and permissions for lay providers to administer tests in community settings. The burden of COVID-19 on health systems has further challenged key population access to HIV, TB, viral hepatitis, and STI testing services and counselling. In response to the pandemic, there is evidence of individual community-based organisations (CBO) initiating diversified testing service delivery options such as self-testing/sampling. While impressive, such interventions are siloed, unfeasible, and unsustainable for many regions.
There is a need for diagnostics developers/manufacturers and community-level organizations to collaboratively initiate sustainable testing interventions and adapt strategic approaches to reach the undiagnosed within key populations.
In continued collaboration with EuroTEST, the EATG will host an initial multi-level stakeholder meeting regarding HIV, TB, viral hepatitis and other STIs diagnostics at HepHIV 2021.
Meeting Objectives
i. Provide a community-level perspective on self-testing/sampling diagnostic tools and testing service delivery ii. Examine diagnostic companies’ plans/commitment to community; specifically, in regards to cost of diagnostics and regulatory/legal barriers
iii. Provide a platform for dialogue between CBOs and Diagnostic developers, and potentially identify collaborative opportunities.
Expected outcomes
Findings from this meeting will be summarized and shared to the main HepHIV 2021 conference attendees. This meeting will contribute to bilateral dialogue on the use of testing technologies to support key population empowerment, early detection, linkage to care, and facilitate HIV management. Dialogue between industry and community will open opportunities for product co-design and implementation, and establish new partnerships.
Agenda
9:30-9:40 9:40-9:55
Welcome and meeting objectives, Magdalena Ankiersztejn-Bartczak, CEO Foundation for Social Education
Community organisations perspectives: experiences with self-test diagnostics
Christos Krasidis, Cyprus Checkpoint
Mihai Lixandru, ARAS - Asociatia Romana Anti-SIDA Robert Hejzak, Czech AIDS Assistance
9:55-10:15
Diagnostics companies plans and commitment to community level
Orasure
Owen Mumford
10:30-10:50
Moderated discussion of opportunities to collaborate
10:50-11:00
Follow-up points & meeting wrap-up, Magdalena Ankiersztejn-Bartczak, CEO Foundation for Social Education
Lisbon Fast Track City: HCV testing and treatment in the community – learning from harm reduction and people who use drugs
HepHIV 2021 conference side-meeting
Time/date: 5 May 2021, 11:30-13:00 CEST
Participants: Open to all conference participants – no pre-registration needed
Meeting background and objectives
During this session, the experience and results of five different HCV treatment outreach interventions in three Fast-Track Cities – Lisbon, Oporto and Paris – will be presented and discussed. The audience will be invited to actively engage in collectively reflecting on the importance of building on learnings from harm reduction and involving peers and how HCV treatment outreach interventions can be further leveraged to achieve elimination of Hepatitis C by 2030.
Agenda
-
-
-
5’ initial intervention by each participant
-
Discussion (open to the audience participation)
-
-
Participants:
-
-
-
Hugo Faria Ares do Pinhal/Mobile Outreach Team
-
Luís Mendão GAT- IN-Mouraria/ Harm Reduction Centre
-
Inês Marinho Crescer/ Outreach Team
-
Sérgio Rodrigues APDES- GIRUGaia/Mobile Outreach Team
-
Elisabeth Avril GAIA Paris/Drug Consumption Room
-
-
Moderators:
-
-
-
Alexis Goosdeel – European Monitoring Centre for Drugs and Drug Addiction
-
Ricardo Fuertes – Câmara Municipal de Lisboa / Lisbon Fast Track City
-
-
Fast-Track Cities: Actioning HCV Elimination in European Urban Settings
HepHIV 2021 Conference Side-Meeting
Time/Date: 13:30-14:30 CEST, 5 May 2021
Participants: Open to all conference participants – no pre-registration needed
Meeting Background
The Paris Declaration on Fast-Track Cities calls upon cities and municipalities around the world to accelerate local actions towards ending their HIV, TB, and viral hepatitis epidemics by 2030. COVID-19 has placed a significant strain on national and subnational health systems at a critical moment in the context of HCV elimination. According to mathematical modelling, the 1-year delay in advancing HCV programmatic targets may have resulted in 44,800 excess hepatocellular carcinoma cases and 72,300 excess liver-related deaths, relative to a no-delay scenario globally, from 2020 to 2030, with the most excess hepatocellular carcinoma and liver-related deaths among high-income countries.1 However, clinician and community leaders across the European Fast-Track Cities network worked diligently and strategically over the past year to maintain a continuity of HCV services with the aim of mitigating disruptions across the HCV care continuum.
Meeting Objectives
The meeting will help define a strategy for actioning HCV elimination in European urban settings in alignment with World Health Organization (WHO) and United Nations (UN) goals and targets. Moreover, the meeting will showcase urban HCV efforts in two European Fast-Track Cities that have leveraged their existing HIV responses to advance HCV elimination goals despite the challenges posed by their cities’ COVID-19 epidemics.
Agenda
|
Time |
Presentation |
Presenter |
|
|
Moderator: Dr José M. Zuniga, President/CEO, IAPAC and Fast-Track Cities Institute |
|||
|
13:30h |
Welcome, Context, and Introductions (5 minutes) |
Dr José M. Zuniga President/CEO IAPAC and Fast-Track Cities Institute |
|
|
13:35h |
Leveraging Fast-Track Cities to End Urban HCV Epidemics: An Urban Agenda to Find and Cure the Missing Millions (10 minutes) |
Mr Cary James President World Hepatitis Alliance |
|
|
Case Studies |
|||
|
13:45h |
HIV and HCV Screening in the Midst of the COVID-19 Pandemic: Seizing an Opportunity across Homeless Shelters in London (10 minutes) |
Prof. Jane Anderson Co-Chair Fast-Track London |
|
|
13:55h |
Urban HCV Micro-Elimination in Action: Examining the AEHVE Hep C Free Experience in Sevilla and Valencia as a Model for Europe (10 minutes, pre-recorded presentation) |
Dr. Javier García-Samaniego Coordinator AEHVE Hep C Free |
|
|
14:05h |
Q&A and Open Discussion (20 minutes) |
Faculty and Participants |
|
|
14:25h |
Review of Key Take-Away Messages (5 minutes) |
Dr José M. Zuniga President/CEO IAPAC and Fast-Track Cities Institute |
|
Reference
-
-
-
- Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74(1):31-36.
-
-
|
Time (CEST) |
Presentation No. |
Session |
Moderators and speakers |
|
15:00-17:00 |
OS |
OPENING SESSION Session objectives: To provide an overview of the conference objectives, scope and expected outcomes of the conference. Set the scene through policy, technical and community perspectives on European progress toward the Sustainable Development Goals and other global targets, including challenges ahead and priorities for maintaining HIV, viral hepatitis, STIs and TB on the political agenda. |
Moderators: Daniel Simões, HepHIV2021 Conference Co-chair, Coalition Plus/GAT, Portugal Jürgen Rockstroh, HepHIV2021 Conference Co-chair, HIV Outpatient Clinic, University of Bonn, Germany |
|
15:00-15:10 |
OS/00 |
Welcome to the HepHIV 2021 Lisbon & Virtual Conference |
Ricardo Baptista Leite, Local conference co-chair, |
|
15:10-15:20 |
OS/01 |
Conference objectives and overview |
Dorthe Raben, EuroTEST Initiative, CHIP, University of Copenhagen |
|
15:20-15:30 |
OS/02 |
Welcome message from the Portuguese Minister of Health |
António Lacerda Sales, Assistant State Secretary for Health, Portugal |
|
15:30-15:40 |
OS/03 |
Welcome from the European Commission: The EU response on HIV, viral hepatitis, STIs and TB in the future |
John Ryan, Director of Public Health, DG Sante, European Commission |
|
15:40-15:50 |
OS/04 |
Post-2020/COVID-19 and progress towards the SDG targets: Where are we? |
Andrea Ammon, Director, European Centre for Disease Prevention and Control (ECDC) |
|
15:50-16:00 |
OS/05 |
‘The changed landscape’ – providing testing for HIV/STIs/hepatitis/TB in the era of COVID-19 |
Hans Kluge, Regional Director, WHO Regional Office for Europe. Represented by Nicole Seguy, WHO Regional Office for Europe in the live discussion |
|
16:00-16:10 |
OS/O6 |
Country Spotlight: Portugal’s progress in reaching the global targets and interventions for integration of testing |
Rui Portugal, Deputy Director-General of Health, National Directorate of the Portuguese Ministry |
|
16:10-16:20 |
OS/07 |
Community perspective on enabling environments for integrated testing and linkage to care across Europe |
Daniel Simões, Coalition Plus/GAT, Portugal |
|
16:20-17:00 |
|
Panel discussion |
|
COBATEST network executive meeting (Closed meeting)
|
Time (CET) |
|
Session |
Moderators and speakers |
|
13:00-14:15 |
PS1 |
PLENARY SESSION 1: SPECIAL SESSION: Impact of COVID-19 on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building back better Session objectives: To share the latest evidence of how the COVID-19 pandemic has impacted prevention, testing and linkage to care for HIV, viral hepatitis and STIs; share successful models of service adaptation and discuss how to build stronger systems and communities in light of lessons learned. |
Moderators: Nicole Seguy, WHO Regional office for Europe Jeffrey Lazarus, Barcelona Institute for Global Health (IS Global) |
|
13:00-13:10 |
PS1/01 |
Keynote address:Perspectives from the US National Institute of Allergy and Infectious Diseases of the National Institutes of Health |
H.Clifford Lane, Deputy Director for Clinical Research and Special Projects , National Institute of Allergy and Infectious Diseases (NIAID), USA |
|
13:10-13:20 |
PS1/02 |
Impact of the COVID-19 pandemic on testing and linkage to care for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region |
A.R. Stengaard1, A. Sullivan2, J.D Kowalska3, C. Rokx4, D. Raben1, D. Simões5, The EuroTEST COVID-19 impact assessment consortium of partners |
|
13:20-13:30 |
PS1/03 |
s.a.m. Health: Germany’s first digital sexual health service is providing COVID-safe remote STI testing and counselling during the Covid-19 Pandemic and beyond |
A. Schafberger1, K.M. Dymek2, G. Waltinger3, G. Davies4, C. Kantwerk1 |
|
13:30-13:40 |
PS1/04 |
Rapid HIV testing and linkage in rehabilitation centers during COVID-19 pandemics, Yekaterinburg and Sverdlovsk region, Russia |
V. Evseeva1, M. Greysman1, V. Stanilevskiy2, N. Mironova2, A. Chuykov3, A.M. Żakowicz3 |
|
13:40-13:50 |
PS1/05 |
European testing week: adaptation of testing services during the COVID-19 pandemic |
B. Collins1, C. Bom Kahama2, D. Raben2 |
|
13:50-14:15 |
|
Discussion |
|
|
14:15-14:30 |
|
Break |
|
|
14:15-14:30 |
|
Break |
|
14:30-15:30 |
AS1 |
ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage Session objectives: To share innovative programmes and experiences for implementing new testing and sampling technologies to increase HIV, viral hepatitis, STI and TB testing coverage based on submitted conference abstracts. |
Moderators: Cary James, World Hepatitis Alliance Valerie Delpech, Public Health England |
|
14:30-14:37 |
AS1/01 |
RiskRadar: the 1st integrated ICT tool on combination prevention for hepatitis/HIV/TB/STI |
L. Cosmaro1, D. Savarino1, M. Mommi2, Z. Dominkovic3, A. Simkunaite-Zazecke4, L. Stoniene5, A. Raahauge6, C. Kakalou7, V. Drosou8, P. Natsiavas7 |
|
14:37-14:44 |
AS1/02 |
An evaluation of the outcomes of an online HIV self-sampling service to inform risk communication and future online testing policy |
J. Taylor1,2, G. Holdsworth1, S. Amos-Gibbs1, E. Ardines1, B. George1, J. Harbottle1, P. Baraitser1,3 |
|
14:44-14:51 |
AS1/03 |
Efficacy of an on-screen computer reminder for HIV screening in primary care based on indicator conditions: a cluster randomized controlled trial |
C. Agustí1,2, O. Cunillera3, J. Almeda3, J. Mascort4,5, R. Carrillo4,5, C. Olmos3, J. Casabona1,2 |
|
14:51-14:58 |
AS1/04 |
Breaking the Chain? A once in a generation opportunity to find and treat HIV during UK’s COVID-19 lockdown |
A. Basu1, B. George1, G. Holdsworth1 |
|
14:58-15:30 |
|
Discussion |
|
|
Poster Session 1 (PO1): Innovative testing services during the COVID-19 pandemic: lessons learned |
||
|
PO1/01 |
Impact of the COVID-19 pandemic on community-based testing for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region |
L. Fernàndez-López1,2, J. Casabona1,2 |
|
PO1/02 |
Screening, diagnosis and treatment of HCV/HIV during the COVID 19 pandemic: lessons from a Mobile Outreach Program in Lisbon, Portugal |
F. Barata1, C. Pereira1, I. Pereira1, H. Faria1, R. Sousa Coutinho1, D. Gil Morais1 |
|
PO1/03 |
Impact of COVID-19 on a Portuguese ONG screening site: implications for practice |
A.L. Rosa1, P. Morais1, E. Sávio1, J. Conceição1, C. Rodrigues1 |
|
PO1/04 |
Strengthening community responses on prevention and care for PLHIV and key populations during the COVID-19 emergency crisis |
M. Reiriz Rojas1, A. Bertó Moran1, D. García Morcillo1 |
|
PO1/05 |
Going cashless in a cash-constrained crisis: Implementation of a COVID-19 emergency response program for optimising engagement in HIV care among Thai men who have sex with men and transgender women |
T. Anand1, C. Nitpolprasert1 |
|
PO1/06 |
Use of mobile applications and social networks for HIV testing among MSM and PrEP obtaining at COVID-19 conditions, in Ukraine |
A. Chernyshev1, A. Bogoslavets1, R. Marchenko1 |
|
Poster Session 2 (PO2): Impact of COVID-19 on provision of services for people who inject/use drugs |
||
|
PO2/01 |
Changes to the provision of services for people who inject drugs in England, Wales and Northern Ireland during the COVID-19 pandemic |
S. Croxford1, E. Emanuel1, A. Ibitoye1, J. Njoroge1, C. Edmundson1, L. Slater1, E. Phipps1 |
|
PO2/02 |
COVID-19 impact on harm reduction programs (testing and counselling) in low threshold drug services in Germany |
A. Krings1, G. Steffen1, C. Germershausen1, R. Zimmermann1 |
|
PO2/03 |
The impact of the COVID-19 pandemic on harm reduction services in a prison and addiction centres in the Balearic Islands, Spain: preliminary results from a novel hepatitis C elimination programme |
A. Herranz1, À. Vilella2, A. Agius3, J.M. Alonso4, A. Rodríguez5, C.A Picchio1, D. Guy1, C. Pujol1, M. Buti6,7, J. Lazarus1 |
|
PO2/04 |
Using peer support to facilitate hepatitis C treatment during the COVID-19 pandemic |
J.S. Lambert1,2, B. West2, T. McHugh1, J. Farrell2, C. Moran2, l. Vidal1 |
|
Poster Session 3 (PO3): New testing technologies to increase testing coverage: HIV self-testing and home-based sampling |
||
|
PO3/01 |
Key learnings from an HIV at-home testing campaign for Dutch MSM and trans people during the COVID-19 pandemic |
K. Vermey1, P. Zantkuijl1, H. Bos1, M. Lasschuyt2, K. Visser2, W. Zuilhof1 |
|
PO3/02 |
Self HIV testing in Poland implementation during COVID-19 |
M. Ankiersztejn-Bartczak1, A. Stola1,2 |
|
PO3/03 |
Preliminary results of a pilot project on HIV self-testing among men who have sex with men in the City of Zagreb, Croatia, 2020/2021 |
N. Bogdanić1, D. Dubravić2, J. Kresović2, M. Erceg2, A. Dišković2, T. Beganović2, Š. Zekan1, J. Begovac1 |
|
PO3/04 |
Get an HIV test at home! Increasing access to testing, in the pandemic context, by implementing a pilot program of home-based HIV testing in Romania |
M. Lixandru1, S. Ciobanu1, C.-L. Hanu1, A. Schiau1 |
|
PO3/05 |
TESTATE C Plus: an online self-sampling intervention for hepatitis C in gay, bisexual and other men who have sex with men and trans women in Catalonia (Spain) |
C. Agustí1,2, H. Martínez1, E. Martró3,2, S. Moreno1, E. Muntada1, P. Romano1, L. Egea1, R. Mora4, L. Villegas4, J. Mena4, Q. Roqueta5, J. Hernández6, M. Vázquez6, A. Not3, A. Pérez3, J. Colom7, J. Casabona1,2 |
|
PO3/06 |
High acceptability and effectiveness of an online self-sampling intervention for HIV in gay, bisexual and other men who have sex with men and trans women in Spain (TESTATE VIH) |
C. Agustí Benito1,2, H. Martínez1, V. González1, S. Moreno1, E. Muntada1, P. Romano1, L. Egea1, R. Muñoz1, J. Hoyos3,2, J. Casabona1,2 |
|
16:30- 17:45 |
PS4 |
PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC) |
Moderators: Anne Bergenström, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Viktor Mravčík, Head of the National Monitoring Centre for Drugs and Addictions, Czechia |
|
16:30-16:40 |
PS4/01 |
Keeping the HIV/Hepatitis targets for PWID on track during the Covid-19 pandemic: European perspectives |
Thomas Seyler, EMCDDA |
|
16:40-16:50 |
PS4/02 |
New evidence on testing and linkage to care for PWIDs |
Otilia Mardh, European Centre for Disease Prevention and Control (ECDC) |
|
16:50-17:00 |
PS4/03 |
Ensuring delivering of testing and linked services for PWID/PWUD during the COVID19 pandemic |
Marios Atzemis, Positive Voice, Greece |
|
17:00-17:10 |
PS4/04 |
What is needed to promote prisons as a setting for case-finding and treatment of infections among PWIDs? |
Fadi Meroueh, Montpellier University Hospital, France |
|
17:10-17:45 |
|
Panel Discussion |
Moderator: Linda Montanari, EMCDDA |
|
16:30-17:45 |
PS2 |
PLENARY SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB Session objectives: To share advances in prevention programming; define the concept of combination prevention in HIV, hepatitis, STIs and TB, highlighting good examples of how combination prevention can be implemented as a strategy and enlarged as a people-centered approach. |
Moderators: Ben Collins, ReShape/International HIV Partnerships Teymur Noori, European Centre for Disease Prevention and Control (ECDC) |
|
16:30-16:40 |
PS2/01 |
“Prevention is hard, Combination is key” – Good example of HIV/STI combination prevention in Scotland |
Claudia Estcourt, Glasgow Caledonian University, Scotland, United Kingdom |
|
16:40-16:50 |
PS2/02 |
Combination disease prevention in prisons: a comprehensive programme in Luxembourg |
Patrick Hoffmann, Luxembourg Directorate of Health |
|
16:50-17:00 |
PS2/03 |
TB an HBV/HCV/HIV-combined preventive activities in the Netherlands |
Gerard de Vries, RIVM, Netherlands |
|
17:00-17:10 |
PS2/04 |
The ‘Get Tested LeEDs’ project: clinical impact and cost-effectiveness of opt-out emergency department testing for bloodborne viruses (BBVs) in England |
E. Smout1, J. Williams2, A. Miners2, K. Phyu3, L Parker3, A Evans3, J McLaren3, M. Aldersley3, G. Hughes1, M. Ruf4, E. Page3 |
|
17:10-17:45 |
|
Discussion |
|
|
17:45-18:00 |
|
Break |
|
18:00-19:30 |
|
EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action Session objectives: To discuss integration of infectious diseases and ways to ensure sustainability and improvement of integrated health care models. |
Moderators: Luis Mendão, GAT Portugal Dorthe Raben, CHIP/INTEGRATE Coordinator |
|
18:00-18:05 |
|
The INTEGRATE Story & INTEGRATE at HepHIV |
Dorthe Raben, CHIP/INTEGRATE Coordinator |
|
18:05-18:30 |
|
Video presentation of the processes behind the main outcomes of the INTEGRATE JA Short intro to the Online training module on prevention, testing and linkage to care |
|
|
18:30-19:30 |
|
Panel discussion: Integration of Infectious Diseases – keeping the momentum |
Valerie Delpech, Public Health England, UK Lella Cosmaro, Lila Milano, Italy Jordi Casabona, El Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Catalonia, Spain Ann Sullivan, SSAT Chelsea Westminister Hospital, UK Nadia Gasbarrini, Villa Maraini, Italy Jack Lambert, University of Dublin & Mater Misericordiae University Hospital, Ireland Walter Cullen, University of Dublin, Ireland Jeff Lazarus, Barcelona Institute for Global Health (IS Global), Catalonia, Spain Teymur Noori, European Centre for Disease Prevention and Control (ECDC) Thomas Seyler, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Ana Gutierrez Burgos, European Commission, DG SANTE |
|
13:00-14:15 |
PS3 |
PLENARY SESSION 3: Implementing integrated testing strategies Session objectives: To present examples of innovative integrated testing programmes for HIV, viral hepatitis, STIs and/or TB and highlight effective implementation models of integrated testing and linkage to care at different service levels. |
Moderators: Jordi Casabona, El Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT) Catalonia, Spain Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC) |
|
|
|
Short report from Day 1 deleted |
|
|
13:00-13:10 |
PS3/01 |
Experience in innovative approach to testing for HIV, hepatitis and STIs |
Raimonda Matulionytė, Vilnius University Hospital Santaros Klinikos, Lithuania |
|
13:10-13:20 |
PS3/02 |
Integrated screening for TB, HIV and HCV at the primary healthcare level |
Maka Danelia, National Center for Disease Control and Public Health, Georgia |
|
13:20-13:30 |
PS3/04 |
Evolution of key indicators for community-based voluntary counseling and testing activity in Europe: COBATEST Network 2017-2019 |
M. Gogishvili1, L. Fernàndez López1,2,3, J. Casabona Barbarà1,2,3 |
|
13:30-13:40 |
PS3/05 |
Implementing self-test programmes during COVID-19 |
Robert Hejzak, Czech AIDS Help Society |
|
13:40-14:15 |
|
Discussion |
|
|
14:15-14:30 |
|
Break |
|
14:30-15:30 |
AS2 |
ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD Session objectives: To share and discuss experiences in implementing testing and care models for people who inject or use drugs and provide European and global overviews of harm reduction and care responses (for people who inject or use drugs), including responses to the global COVID-19 pandemic. |
Moderators: Eberhard Schatz, Correlation Network Lella Cosmaro, Lila Milano, Italy |
|
14:30-14:37 |
AS2/01 |
Testing and linkage to care services for 1000 people who inject drugs from Bucharest through the implementation of a three level HCV elimination strategy |
S. Ciobanu1, A. Bocai1, M. Dan1, A. Luca1, R. Teodorescu1 |
|
14:37-14:44 |
AS2/02 |
Integrated harm reduction responses to HIV and viral hepatitis in the COVID-19 pandemic: a global overview |
S. Shirley-Beavan1, R. Csak1, C. Daniels1, N. Burke-Shyne1, G. Lasco2, M. Platko3, J. di Iorio4, C. Ahumada4, S. Hajal5, E. Aaraj5, C. Baguma6, K. Naik7 |
|
14:44-14:51 |
AS2/03 |
Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan, Italy |
S. Mazzilli1,2, T. Sebastiani3, V. Casigliani1, G. Cocca3, A. Stemat3, C. Nicola3, C. Selva3, C. Catani3, L. Tavoschi1, R. Ranieri3 |
|
14:51-14:58 |
AS2/04 |
Blood-borne virus testing in people who inject drugs with a history of sex work |
E. Emanuel1, S. Croxford1, E. Phipps1, A. Ibitoye1, J. Njoroge1, C. Edmundson1, L. Slater1 |
|
14:58-15:05 |
AS2/05 |
HCV care for PWID in Europe - results from a civil society-led monitoring |
R. Rigoni1, T. Tammi2, E. Schatz1 |
|
15:05-15:30 |
|
Discussion
|
|
|
Poster Session 4 (PO4): Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings |
||
|
PO4/01 |
Socio-demographic inequalities in HIV testing patterns among MSM in Spain |
C. Folch1, A. Díaz2, M.C. Vázquez3, S. Meyer4, J. Casabona1 |
|
PO4/02 |
Towards a hepatitis C-free hospital: results after one year of hepatitis C virus screening in a tertiary hospital emergency department in a high-income country |
J. Llaneras Artigues1, A. Barreira-Díaz1, A. Rando Segura1, J. Bañares Sanchez1, B. Meza Ramos1, L. Ruíz Ortega1, J.R. Marques Soares1, A. Monforte Pallares1, O. Orozco Gálvez1, M. Riveiro-Barciela1, F. Velasquez Orozco1, F. Rodríguez-Frías1, M. Arranz Betegon1, R. Esteban Mur1, M. Buti Ferret1 |
|
PO4/03 |
Implementation of HIV rapid testing model in government medical facilities in Leningrad Region, Russia in 2020 |
S. Semikova1, P. Supronenko2, V. Stanilevskiy2, M. Petrova3, O. Prokof’eva4, V. Surkova5, A. Merzlyakova6, Y. Godunova6, A. Kovelenov1, A. Chuykov2, N. Mironova2, A. Zakowicz7 |
|
PO4/04 |
Quality of life in people living with HIV in Romania and Spain |
J. Lazarus2, M. Kall1, U. Fresán2,3, D. Guy2, G. Brown4, C. Burgui5, J. Castilla5, V. Ionel Grecu6, F. Dumitrescu6, V. Delpech1 |
|
PO4/05 |
HCV screening of immigrants at arrival: an opportunity to linkage to care of a population with limited access to Health Care system |
M. Riveiro-Barciela1,2, B. Treviño3, N. Serre3, A. Rando4, F. Salvador3, A. Barreira-Díaz1, A. Palom1, E. Vargas1, D. Pou3, L. Roade1,2, I. Molina3, F. Rodríguez-Frías2,4, M. Buti1,2 |
|
PO4/06 |
Expanding integrated HCV/HIV testing to alcohol dependent clients attending treatment centres for drug and alcohol dependency in Lithuania |
L. Stoniene1, E Subata1, A Sirvinskiene1, A Grice1, M.L. Jakobsen2, S. Finne Jakobsen2, D. Raben2, C. Rae3, A. Sullivan3 |
|
PO4/07 |
Distributing a questionnaire for women attending a Sexual Health Clinic increases PrEP uptake |
S. Strachan1,2, S. Jaffer1, V. Apea3, D. Campbell4, J. Domino5, L. Davies1, J. Dugdale6, K. Nambier7, D. Onyago8, J. Otti2, M. Ross9, J. Stevenson2, N. Turner1, G. Singh1, A. Sullivan1 |
|
PO4/08 |
HIV and viral hepatitis transmission knowledge among female health care providers and females in the general population in Constanta Region, Romania |
A.-M. Schweitzer1, M. Bogdan1, F.S. Stoian1, I. Ciocea1 |
|
Poster Session 5 (PO5): Integrated testing programmes for hepatitis/HIV/TB/STI: community-based settings |
||
|
PO5/01 |
Community-based voluntary counseling and testing for HIV, sífilis and HCV in Europe: COBATEST Network 2019 |
M. Gogishvili1, L. Fernàndez López1,2,3, J. Casabona Barbara1,2,3 |
|
PO5/02 |
Rapid Hiv test in Sardinia, a lookback at first 5 years of Lila Cagliari testing service |
G. Dessì1, F. Cardinale1, V. Mascia1
|
|
PO5/03 |
Reaching 95-95-95: 3 years of the Portuguese League Against AIDS performing screening tests and promoting therapeutical compliance |
M.E. Saraiva1, S. Melo Refoios1,2, M. Ferrão1, G. Bento3, R. Castro4, R. Vicente5, L. Nunes5 |
|
PO5/04 |
Promoting autonomy and self-care of people living with HIV and/or hepatitis through a community-based approach: the example of the Takari project in French Guiana |
A.-S. Petit1,2, J.-P. Dada3, L. Napuchi3, C. Mathurin4, M. Shahisavandi4, M. Préau1, D. Michels2,5, M. Gaillet6, C. Michaud6, C. Piedrafita y Costa3 |
|
PO5/05 |
Contributions of (+) Screening = (+) Life Project in the access of the Trans and Sex Worker population to early detection and screening of STIs |
P. Costa1, F. Aguiar1, S. Correia1, A. Silva2, P. Belmonte1, F. Neves3 |
|
Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs |
||
|
PO6/01 |
Point-of-care screening combined with nursing and peer-based outreach work to enhance testing and treatment for hepatitis C among people who use drugs, people who experience homelessness, and migrants: the REACH U Study |
C. Merendeiro1, R. Lopes1, I. Marinho1, R. Marinho2, J. Grebely3, A. Nave1 |
|
PO6/02 |
Efficiency of HIV rapid testing and social services for IDU women in Tomsk, Russia |
E. Borzunova1, A. Chernov2, V. Stanilevskiy3, N. Mironova3, A. Chuykov4, A.M. Żakowicz4 |
|
PO6/03 |
Hepatitis C cascade of care (CoC) for people who use drugs (PWUD) under opiate substitution treatment (OST) in Greece |
O. Anagnostou1, K. Micha1, K. Kaliva1, E. Tsirogianni1, E. Petroulaki1, I. Detsi1, M. Kollitsida1, G. Androulakis1, M. Gargoulaki1, V. Karagounis1, A. Katsili1, S. Kollia1, A. Kotsalis1, M. Spirellis1, K. Stamatopoulos1, V. Stavridou1, C. Tanis1, P. Tsekoura1, Y. Topalidou Stepin1, A. Tsantilas1, M. Chalkiadakis1, A. Drimousi1, N. Papadopoulos2, A. Theocharis1 |
|
PO6/04 |
Decentralized HCV consultation: an HCV micro-elimination project in the community |
Á. Ávila1, T. Azevedo1, M.J. Braz1, S. Busi1, F. Calinas2, R. Costa1, T. Mamede1, C. Marques1, R. Pires1, J. Santa Maria1 |
|
PO6/05 |
Portugal’s first mobile drug consumption room: client characteristics and linkage to care |
H. Taylor1, A. Curado1, Â. Leite1, J. Pires2, V. Correia1, P. Nunes2, J. Caldas1, M. Alves2, J. Canêdo1, D. Gautier2 |
|
PO6/06 |
Could the 2010 HIV outbreak in Athens, Greece be prevented? A mathematical modelling study |
I. Gountas1, G. Nikolopoulos2, G. Touloumi3, A. Fotiou4, K. Souliotis1 |
|
PO6/07 |
Eliminating hepatitis C on the Balearic Islands by linking patients who use drugs from addiction service centers, a local NGO, a prison and a mobile methadone bus to HCV care |
J.V Lazarus1, À. Vilella2, C.A Picchio1, A. Herranz1, M. Buti3,4 |
|
PO6/08 |
Effectiveness of an HIV care model integrated into addiction care based on medication-assisted treatment for HIV-positive people who use drugs (PWUD) |
J. Valencia1, P. Ryan1, J. Lazarus2, J. Troya1, G. Cuevas1, I. Cañamares1, I. Escobar1 |
|
PO6/09 |
Designing a strategy to reengage PWID lost to follow-up in HIV care, the case of the PISCIS Cohort in Spain |
J. Palacio-Vieira1,2, J.M. Reyes-Urueña1,2,3, A. Imaz4, A. Bruguera1,3, L. Force5, A.-J. Orti-Llaveria6, J.-M Llibre7, I. Vilaró8, F. Homar Borràs9, V. Falcó10,11, M. Riera12, P. Domingo13, E. de Lazzari14, I. Chivite14, E. Letang15, J.-M Miró14, J. Casabona1,2,3,16 |
|
PO6/10 |
Impact of opiate substitution treatment (OST) on hepatitis and HIV high risk behaviors |
M. Vasileiou1, O. Anagnostou2, I. Elefsiniotis3 |
|
16:30- 17:45 |
PS4 |
PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC) Session objectives: To provide an overview of the latest evidence on prevention, testing and linkage to care for people who use or inject drugs, highlighting the importance of prison settings for increasing diagnosis and care for people who inject drugs, and to discuss the impact of COVID-19 on the provision of services for people who use drugs. |
Moderators: Anne Bergenström, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Viktor Mravčík, Head of the National Monitoring Centre for Drugs and Addictions, Czechia |
|
16:30-16:40 |
PS4/01 |
Keeping the HIV/Hepatitis targets for PWID on track during the Covid-19 pandemic: European perspectives |
Thomas Seyler, EMCDDA |
|
16:40-16:50 |
PS4/02 |
New evidence on testing and linkage to care for PWIDs |
Otilia Mardh, European Centre for Disease Prevention and Control (ECDC) |
|
16:50-17:00 |
PS4/03 |
Ensuring delivering of testing and linked services for PWID/PWUD during the COVID19 pandemic |
Marios Atzemis, Positive Voice, Greece |
|
17:00-17:10 |
PS4/04 |
What is needed to promote prisons as a setting for case-finding and treatment of infections among PWIDs? |
Fadi Meroueh, Montpellier University Hospital, France |
|
17:10-17:45 |
|
Panel Discussion |
Moderator: Linda Montanari, EMCDDA |
|
17:45-18:00 |
|
Break |
|
|
17:45-18:00 |
|
Break |
18:00-19:15 |
|
CLOSING SESSION: Integrating disease areas and settings Session objectives: To discuss lessons learned and next steps for integration of service delivery in infectious diseases; to present and discuss the Conference Call to Action and implications for policy and implementation agendas. |
Moderator: Michel Kazatchkine, Special Advisor to the Joint United Nations Program on AIDS (UNAIDS) for Eastern Europe and Central Asia |
|
18:00-18:15 |
|
Short report from Conference Days 1 and 2 and Best Poster Award |
Jürgen Rockstroh, HepHIV2021 Conference Co-chair, HIV Outpatient Clinic, University of Bonn, Germany |
|
18:15-19:05 |
|
Panel Discussion: Integrated testing and linkage to care for HIV, viral hepatitis, TB, STIs and other infectious diseases: Paving the way forward amidst a global pandemic |
Panellists: Cary James, World Hepatitis Alliance Andrew Winter, IUSTI Europe Jens Lundgren, CHIP, University of Copenhagen Nicole Seguy, WHO Regional Office for Europe Yazdan Yazdanpanah, ANRS Maladies Infectieuses Emergentes, France Nikoloz Chkhartishvili, Infectious Diseases, AIDS & Clinical Immunology Research Center (IDACIRC), Georgia Nikos Dedes, European AIDS Treatment Group (EATG) Ricardo Baptista Leite, MP Portugal, UNITE |
-
EATG stakeholder meeting regarding diagnostics09:30 - 11:00
-
Lisbon Fast Track City: HCV testing and treatment in the community – learning from harm reduction and people who use drugs11:30 - 13:00
-
Fast-Track Cities: Actioning HCV Elimination in European Urban Settings13:30 - 14:30
-
OPENING SESSION15:00 - 17:00
-
COBATEST network executive meeting (Closed meeting))10:00 - 13:00
-
PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: COVID-19’s impact on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building stronger systems and communities in light of lessons learned13:00 - 14:15
-
Break14:15 - 14:30
-
ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage14:30 - 15:30
-
E-poster sessions (live Q&A)/break15:30 - 16:30
-
PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC)16:30 - 17:45
-
PLENARY/ABSTRACT DRIVEN SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB16:30 - 17:45
-
Break17:45 - 18:00
-
EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action18:00 - 19:30
-
PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: COVID-19’s impact on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building stronger systems and communities in light of lessons learned13:00 - 14:15
-
Break14:15 - 14:30
-
ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD14:30 - 15:30
-
E-poster sessions (live Q&A)/Break15:30 - 16:30
-
PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC)16:30 - 17:45
-
Break17:45 - 18:00
-
CLOSING SESSION: Integrating disease areas and settings18:00 - 19:15